+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the anti-tumor activity and safety of amivantamab, alone and combined with standard chemotherapy, in participants with advanced or metastatic colorectal cancer. This study focuses on different groups based on prior treatments and tumor characteristics, aiming to find effective dosing for amivantamab combined with standard chemotherapy. The study includes participants with specific genetic tumor profiles and performance status, assessing treatment effects in various cohorts. Participants receive intravenous infusions of amivantamab alone or with chemotherapy regimens such as mFOLFOX6 or FOLFIRI, depending on their cohort and prior treatment history. The treatment cycles last 28 days and continue until the end of treatment visit, which occurs up to 30 days after discontinuation. Dose levels and schedules vary by cohort, with some receiving monotherapy and others combination therapies at doses determined in earlier phases. Throughout the study, participants undergo physical exams, performance status assessments, laboratory tests, vital sign monitoring, and adverse event tracking. Tumor response and disease control are measured using standard criteria over up to four years and three months. Biopsies are required for certain cohorts to assess tumor characteristics. Safety and treatment effects are closely monitored during and after treatment to evaluate amivantamabs impact.

Age: 18Years +All GendersPhase 1Phase 2
53 locations
E

Actively Recruiting

Researchers are evaluating Datopotamab Deruxtecan Dato-DXd alone and combined with other anticancer drugs in patients with advanced or metastatic solid tumors. This Phase II, open-label, multicenter study uses a modular master protocol to assess safety, tolerability, recommended dosing, and effectiveness across several cancer types including endometrial, gastric, prostate, ovarian, colorectal, urothelial, and biliary tract cancers. The study allows simultaneous evaluation of Dato-DXd in various treatment combinations and disease settings. Participants receive Dato-DXd intravenously as monotherapy or combined with approved or novel anticancer agents, varying by cancer subtype. Treatment combinations include capecitabine, 5-Fluorouracil, prednisoneprednisolone, carboplatin, bevacizumab, volrustomig, rilvegostomig, and cisplatin. Each substudy tests either monotherapy or combination therapy tailored to the tumor type. The study follows participants during treatment and a safety follow-up period, with some treatments administered orally or intravenously depending on the agent. Throughout the approximately one-year study period, participants undergo regular assessments including tumor measurement, adverse event monitoring, pharmacokinetic sampling, and specific biomarker evaluations such as PSA, CA-125, and radiographic progression depending on cancer type. Researchers evaluate outcomes like objective response rate, progression-free survival, disease control, and overall survival. Safety is monitored closely during and up to 28 or 90 days after treatment discontinuation. Participants provide tumor samples for tissue analysis and may consent to optional genetic research.

Age: 18Years - 130YearsAll GendersPhase 2
96 locations